British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG’s skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.
The deal will give Clinigen global rights to the drug and the company expects the deal to add to its profitability this year, and forecast a growth in adjusted EBITDA for the six months ended December.
Date: April 08, 2019
Source: Reuters
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.